Immunooncology spinout Neoleukin Therapeutics is working on a safer, synthetic replica of a T-cell-boosting protein called interleukin-2.
University of Washington has officially unveiled US-based spinout Neoleukin Therapeutics to commercialise an immunooncology drug that will aim to bolster the patient’s T-cell receptors, GeekWire reported yesterday. Founded in November 2018, Neoleukin is aiming to develop a synthetic version of an immuno-stimulating protein called interleukin-2 (IL-2) that enhances the patient’s T-cell receptors so that they can…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
